IDT Biologika GMBH
Dessau-Roßlau, SA
- UEI
- E14GD5J873N9
- CAGE
- D3395
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- Am Pharmapark, 06861 Dessau-Roßlau, Germany
- Website
- idt-biologika.de
- Founded
- 1921
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$265,880 |
| FY2025 | -$7,748 |
| FY2024 | $4,226,465 |
| FY2023 | $2,598,203 |
Contract vehicles
No active vehicles.
1 expired vehicle
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Thomas Jefferson University | HHSN272201700082C | $8,296,135 |
Similar vendors
About the company
IDT Biologika GMBH is a German biotechnology company that provides end-to-end services for pharmaceutical and biotech companies, specializing in the contract manufacturing of vaccines, viral vectors for cell and gene therapeutics, oncolytic viruses, protein-based vaccines, and other biologics. It is a foreign-owned, for-profit corporate entity registered to receive federal awards from the U.S. government.
IDT Biologika GMBH has been awarded several prime federal contracts by the Department of Health and Human Services' National Institutes of Health (NIH) and its National Institute of Allergy and Infectious Diseases (NIAID). These contracts involve the development, manufacturing, and characterization of various biological materials for infectious disease research and pandemic preparedness efforts. Specific products and services provided under these contracts include influenza virus human challenge material for clinical trials, process development and master bank production for Staphylococcus aureus protein A, development and manufacturing of toxoid fusion proteins and master cell banks, master cell bank manufacturing for COVID-19 pandemic preparedness, process development for vaccine candidates including SARS-CoV-2, and vaccine manufacturing and characterization services for influenza virus and SARS-CoV-2 materials. The contracts are primarily delivery order agreements with firm fixed price or cost-plus-fixed-fee pricing structures and range in value from hundreds of thousands to tens of millions of dollars. No set-aside designations or subcontractors have been identified for these awards.
Quick answers
Is IDT Biologika GMBH registered in SAM.gov?
Yes. IDT Biologika GMBH's SAM.gov registration is active through February 6, 2027.
Which contract vehicles does IDT Biologika GMBH hold?
IDT Biologika GMBH holds a place on 1 federal contract vehicle: Respiratory Illness Live Virus Fill / Finish Services.
How much has IDT Biologika GMBH received in federal contracts?
Federal contracts obligated $6,551,040 to IDT Biologika GMBH in fiscal years 2023 through 2027.
What is IDT Biologika GMBH's most recent federal award?
IDT Biologika GMBH's most recent federal contract award is Manufacture of influenza virus human challenge material for phase 1 and 2 (75N93023F00001), from National Institute of Allergy and Infectious Diseases (NIH), on September 26, 2023.
On GovTribe
See IDT Biologika GMBH's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors